CD274 and non-small cell lung carcinoma: Although ipilimumab and tremelimumab remain under investigation in combination with PD-1/PD-L1 inhibitors and chemotherapy, the risk–benefit ratio appears less favourable in unselected NSCLC and SCLC populations.